- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00331682
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
An Open-Label, Non-Randomized Phase II Study of Alvocidib (Flavopiridol) in Combination With Docetaxel in Refractory, Metastatic Pancreatic Cancer (NCI #6366)
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the response rate in patients with refractory, metastatic pancreatic cancer treated with weekly, sequential docetaxel and flavopiridol.
SECONDARY OBJECTIVES:
I. Determine the time to progression and overall survival of patients treated with this regimen.
II. Assess the toxicity of this regimen.
OUTLINE: This is a non-randomized, open-label, prospective study.
Patients receive docetaxel IV over 30 minutes followed 4-6 hours later by flavopiridol IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically or cytologically confirmed adenocarcinoma of the pancreas
- Evidence of metastatic disease
Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20mm with conventional techniques or as ≥ 10 mm with spiral CT scan
- The primary site is not a measurable lesion
Documented progression with measurable metastatic disease including any 1 of the following criteria:
- Receiving adjuvant therapy for resected disease
- Receiving therapy for locally advanced disease
- Within 3 months of completing adjuvant therapy or therapy for locally advanced disease
- On 1 prior regimen in the metastatic setting
- No documented brain metastases
- Karnofsky performance status (PS) 80-100% OR ECOG PS 0-1
- WBC ≥ 2,500/mm³
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST and ALT < 2.5 times ULN
- Creatinine normal OR creatinine clearance ≥ 60 mL/min
- Alkaline phosphatase ≤ 5 times ULN
- No history of allergic reactions to compounds of similar chemical orbiological composition to flavopiridol
- No known allergy to docetaxel or medications formulated in polysorbate 80 (Tween 80)
- No uncontrolled diabetes
No uncontrolled intercurrent illness including, but not limited to any of the following:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
Cardiac arrhythmia or myocardial infarction within the past 6 months
- Rate-controlled atrial fibrillation stable for ≥ 6 months allowed
- Psychiatric illness or social situations that would limit compliance with study requirements
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
- No peripheral neuropathy > grade 1
- No immune deficiency
- Atl east 2 weeks since prior chemotherapy (6 weeks for nitrosoureas, carmustine, or mitomycin C) and recovered
- At least 2 weeks since prior targeted therapy (e.g., antiangiogenic therapy [e.g., bevacizumab] or epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor [e.g., erlotinib hydrochloride]) and recovered
- At least 4 weeks since prior radiation therapy
- No prior docetaxel or flavopiridol
- No other concurrent chemotherapy or investigational agents
- No other concurrent anticancer agents or therapies
No concurrent commonly used vitamins, antioxidants, orherbal preparations or supplements
- Single-tablet multivitamin allowed
- No concurrent combination antiretroviral therapy for HIV-positive patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (docetaxel and alvocidib)
Patients receive docetaxel IV over 30 minutes followed 4-6 hours later by flavopiridol IV over 60 minutes on days 1, 8, and 15.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate as Measured by RECIST Criteria
Time Frame: Up to 2 years
|
Objective response rate as measured by RECIST criteria
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Progression
Time Frame: Between the start of treatment until the criteria for progression are met, assessed up to 2 years
|
Will be computed using Kaplan-Meier methods.
|
Between the start of treatment until the criteria for progression are met, assessed up to 2 years
|
Overall Survival
Time Frame: Between the start of treatment until patient death, assessed up to 2 years
|
Will be computed using Kaplan-Meier methods.
|
Between the start of treatment until patient death, assessed up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eileen O'Reilly, Memorial Sloan Kettering Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Docetaxel
- Alvocidib
Other Study ID Numbers
- NCI-2012-01471
- 05-136
- R01CA067819 (U.S. NIH Grant/Contract)
- MSKCC-05136
- NCI-6366
- CDR0000472413
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma of the Pancreas
-
Centre Leon BerardMerck Sharp & Dohme LLC; Debiopharm International SACompletedAdenocarcinoma of the Pancreas | Adenocarcinoma of the Rectum | Adenocarcinoma of the ColonFrance
-
Samyang Biopharmaceuticals CorporationUnknownMetastatic Adenocarcinoma of the Pancreas | Recurrent Adenocarcinoma of the PancreasKorea, Republic of
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin Pharma, Inc.; Teva PharmaCompletedAdenocarcinoma of the Pancreas | Solid Tumour | Adenocarcinoma of the Colorectal
-
University of Michigan Rogel Cancer CenterCompletedAdenocarcinoma of the PancreasUnited States
-
National Cancer Institute, NaplesRecruitingAdenocarcinoma of the PancreasItaly, Spain
-
West Virginia UniversityRecruitingAdenocarcinoma of the PancreasUnited States
-
Baptist Health South FloridaAstraZenecaTerminatedAdenocarcinoma of the PancreasUnited States
-
Institut de Recherches Internationales ServierNot yet recruitingMetastatic Adenocarcinoma of the PancreasJapan
-
National Taiwan University HospitalRecruitingDuctal Adenocarcinoma of the PancreasTaiwan
-
Eastern Regional Medical CenterTerminatedMetastatic Adenocarcinoma of the PancreasUnited States
Clinical Trials on alvocidib
-
National Cancer Institute (NCI)CompletedLymphoma | Small Intestine Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedEndometrial CancerUnited States, Canada, Norway, United Kingdom, Australia
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)CompletedLymphomaUnited States
-
Sumitomo Pharma America, Inc.TerminatedAcute Myeloid Leukemia (AML)United States
-
NCIC Clinical Trials GroupCompleted
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
National Cancer Institute (NCI)Completed
-
NCIC Clinical Trials GroupCompletedSarcomaCanada, United States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedLeukemiaUnited States